November 26, 2025

FDA OKs Sarepta Study of New Immune Suppression Approach with Elevidys; Gilead Acquires Preclinical TREX1 Program

2 hours ago talkbio0Tagged acute liver injury, ELEVIDYS, gene therapy, Gilead, Muscular Dystrophy, Duchenne, sirolimus, Therapeutic immunosuppression, TREX1 gene, United States Food and Drug Administration

FDA; Sarepta; Elevidys; immunosuppression; Duchenne muscular dystrophy; Gilead; TREX1; gene therapy; sirolimus; acute liver injury

CMS Unveils Negotiated Prices for Ozempic, Wegovy, and Other Drugs in Second Round of IRA Talks

2 hours ago talkbio0Tagged drug price, Effectiveness, Inflation Reduction Act, Medicare Part D, Myasthenic Syndromes, Congenital, negotiation, Ozempic, Prices, semaglutide, Wegovy

CMS; Ozempic; Wegovy; Inflation Reduction Act; drug price negotiation; Medicare Part D; semaglutide; negotiated prices; 2027 effective date

Zentek Appoints Mohammed Jiwan as CEO

4 hours ago talkbio0Tagged Appointments, CEO, commercialization, Graphene, Jiwan, Mohammed, Nanostructured Materials, Technology, ZenGUARD, Zentek

Zentek; Mohammed Jiwan; CEO appointment; ZenGUARD; nanomaterials; graphene; technology; commercialization

Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCr Bioconjugation Platform

4 hours ago talkbio0Tagged Bioconjugation Platform, CDMO, CliCr, co-exclusive license, Cristal Therapeutics, Curapath, Drug Delivery Systems, nucleic acid delivery

Curapath; Cristal Therapeutics; CliCr Bioconjugation Platform; co-exclusive license; nucleic acid delivery; CDMO; drug delivery

Dupixent Gains EU Approval as First Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade

4 hours ago talkbio0Tagged Approved, Chronic Spontaneous Urticaria, Dupixent, EU, Interleukin-13, interleukin-4, Monoclonal Antibodies, Regeneron, sanofi, type 2 inflammation

Dupixent; chronic spontaneous urticaria (CSU); EU approval; Sanofi; Regeneron; monoclonal antibody; IL-4; IL-13; CUPID phase 3 trials; type 2 inflammation